BRPI1007358A2 - inibidores de poli (adp-ribose) polimerase (parp) - Google Patents

inibidores de poli (adp-ribose) polimerase (parp)

Info

Publication number
BRPI1007358A2
BRPI1007358A2 BRPI1007358-2A BRPI1007358A BRPI1007358A2 BR PI1007358 A2 BRPI1007358 A2 BR PI1007358A2 BR PI1007358 A BRPI1007358 A BR PI1007358A BR PI1007358 A2 BRPI1007358 A2 BR PI1007358A2
Authority
BR
Brazil
Prior art keywords
parp
adp
ribose
polymerase
inhibitors
Prior art date
Application number
BRPI1007358-2A
Other languages
English (en)
Portuguese (pt)
Inventor
R. Gangloff Anthony
John Jennings Andrew
Jones Benjamin
A. Kiryanov Andre
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42271897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007358(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of BRPI1007358A2 publication Critical patent/BRPI1007358A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
BRPI1007358-2A 2009-01-23 2010-01-21 inibidores de poli (adp-ribose) polimerase (parp) BRPI1007358A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14674009P 2009-01-23 2009-01-23
US61/146,740 2009-01-23
US22887909P 2009-07-27 2009-07-27
US61/228,879 2009-07-27
PCT/US2010/021669 WO2010085570A1 (en) 2009-01-23 2010-01-21 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

Publications (1)

Publication Number Publication Date
BRPI1007358A2 true BRPI1007358A2 (pt) 2018-03-06

Family

ID=42271897

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007358-2A BRPI1007358A2 (pt) 2009-01-23 2010-01-21 inibidores de poli (adp-ribose) polimerase (parp)

Country Status (23)

Country Link
US (5) US7928105B2 (enExample)
EP (1) EP2389379A1 (enExample)
JP (1) JP5567599B2 (enExample)
KR (1) KR101779137B1 (enExample)
CN (1) CN102341394B (enExample)
AU (1) AU2010206744B2 (enExample)
BR (1) BRPI1007358A2 (enExample)
CA (1) CA2750106A1 (enExample)
CL (1) CL2011001754A1 (enExample)
CO (1) CO6410305A2 (enExample)
CR (1) CR20110452A (enExample)
DO (1) DOP2011000237A (enExample)
EA (1) EA020301B1 (enExample)
EC (1) ECSP11011284A (enExample)
IL (1) IL213993A (enExample)
MA (1) MA33053B1 (enExample)
MX (1) MX2011007741A (enExample)
MY (1) MY152386A (enExample)
NZ (1) NZ594322A (enExample)
PE (1) PE20120418A1 (enExample)
SG (1) SG172958A1 (enExample)
TN (1) TN2011000339A1 (enExample)
WO (1) WO2010085570A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341394B (zh) 2009-01-23 2015-04-15 武田药品工业株式会社 聚(adp-核糖)聚合酶(parp)抑制剂
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
FI3461825T3 (fi) * 2011-09-30 2023-08-17 C&C Res Lab Uusia heterosyklisiä johdannaisia ja niiden käyttöjä
KR20220137154A (ko) 2012-01-20 2022-10-11 데니스 엠. 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
EP2935261A1 (de) * 2012-12-20 2015-10-28 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydrochinoxalinone
CN103923088B (zh) * 2013-01-11 2016-09-07 上海汇伦生命科技有限公司 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
EP3019493B1 (de) * 2013-07-09 2017-06-14 Bayer Pharma Aktiengesellschaft Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP2017504650A (ja) * 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
KR102310128B1 (ko) * 2014-07-14 2021-10-06 주식회사 포스코 트리아진-피페라진 골격을 갖는 알파-헬릭스 유사체 및 이의 제조방법
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
SG11201703414VA (en) 2014-10-27 2017-05-30 Tensha Therapeutics Inc Bromodomain inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
US11096909B2 (en) 2016-04-06 2021-08-24 University Of Oulu Compounds for use in the treatment of cancer
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
EP3267192B1 (en) * 2016-07-07 2020-08-19 Alpha M.O.S. Gas chromatograph comprising metal oxide sensors
CN106883232B (zh) * 2017-03-31 2019-01-22 苏州康润医药有限公司 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用
CN114144413B (zh) * 2019-07-19 2024-08-16 阿斯利康(瑞典)有限公司 Parp1抑制剂
CN111097386B (zh) * 2019-12-26 2022-01-11 江苏大学 一种二维层状水稳定染料吸附剂及制备方法
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
WO2022225934A1 (en) * 2021-04-19 2022-10-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
CA3213029A1 (en) * 2021-04-22 2022-10-27 Yuli Xie Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN116710433A (zh) * 2021-04-23 2023-09-05 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
CN118043322A (zh) * 2021-09-30 2024-05-14 西藏海思科制药有限公司 含氮杂环衍生物parp抑制剂及其用途
US20240391937A1 (en) * 2021-09-30 2024-11-28 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
PE20241129A1 (es) 2021-10-01 2024-05-24 Xinthera Inc Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
MX2024006074A (es) * 2021-11-19 2024-06-28 Kangbaida Sichuan Biotechnology Co Ltd Inhibidor de parp1 selectivo y aplicacion del mismo.
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
KR20240144125A (ko) * 2021-12-17 2024-10-02 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 Parp 억제제, 이를 포함하는 약제학적 조성물, 및 이의 용도
MX2024008771A (es) * 2022-01-13 2024-09-23 Acerand Therapeutics Hong Kong Ltd Derivado que contiene anillo de piperazino, su sal farmacéuticamente aceptable, su método de preparación y su aplicación.
CN118804916B (zh) 2022-01-21 2025-04-01 新特拉有限公司 Parp1抑制剂及其用途
AU2023229992A1 (en) * 2022-03-11 2024-10-10 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and the use thereof
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
IL316278A (en) 2022-04-28 2024-12-01 Xinthera Inc TRICYCLIC PARP1 INHIBITORS AND THEIR USES
CN117263943A (zh) * 2022-09-09 2023-12-22 轩竹生物科技股份有限公司 聚（adp核糖）聚合酶选择性抑制剂
CN120112531A (zh) * 2022-10-20 2025-06-06 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
CN119948029A (zh) * 2022-11-10 2025-05-06 上海海和药物研究开发股份有限公司 一种稠合三环类parp1抑制剂、其制备方法及用途
IL320545A (en) * 2022-11-10 2025-06-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Fused bicyclic compound
WO2024173781A1 (en) * 2023-02-16 2024-08-22 Ohio State Innovation Foundation Type ii topoisomerase inhibitors and methods of making and using thereof
KR20250154499A (ko) * 2023-03-01 2025-10-28 임팩트 테라퓨틱스 (상하이), 인코포레이티드 Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도
WO2024255697A1 (zh) * 2023-06-13 2024-12-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
US12258345B1 (en) 2023-12-12 2025-03-25 King Faisal University Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) * 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
US4446323A (en) * 1983-05-23 1984-05-01 American Home Products Corporation Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline derivatives
US5166344A (en) * 1989-05-31 1992-11-24 Berlex Laboratories, Inc. Process for the preparation of imidazoquinoxalinones
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
TW274550B (enExample) * 1992-09-26 1996-04-21 Hoechst Ag
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
GB0206219D0 (en) * 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4948178B2 (ja) * 2003-12-10 2012-06-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての置換６−シクロヘキシルアルキル置換２−キノリノンおよび２−キノキサリノン
BRPI0512261A (pt) * 2004-06-17 2008-02-26 Wyeth Corp antagonistas de receptor de hormÈnio liberador de gonadotropina
AU2005327921A1 (en) 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
US7947682B2 (en) * 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
US20090093489A1 (en) * 2004-12-29 2009-04-09 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
AU2006203946B2 (en) * 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006125179A1 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0615809D0 (en) 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
US20100113484A1 (en) * 2006-12-13 2010-05-06 Aska Pharmaceutical Co., Ltd. Treating agent of uropathy
KR101563103B1 (ko) * 2006-12-13 2015-10-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
PH12012501544A1 (en) * 2006-12-28 2024-06-03 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
CN101302214B (zh) * 2007-05-11 2012-06-20 江苏国华投资有限公司 芳烷基哌啶(嗪)衍生物及在治疗精神神经疾病中的应用
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102341394B (zh) 2009-01-23 2015-04-15 武田药品工业株式会社 聚(adp-核糖)聚合酶(parp)抑制剂
US8551996B2 (en) 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment

Also Published As

Publication number Publication date
CO6410305A2 (es) 2012-03-30
CR20110452A (es) 2012-02-28
US8822470B2 (en) 2014-09-02
US8124606B2 (en) 2012-02-28
SG172958A1 (en) 2011-08-29
US20150031652A1 (en) 2015-01-29
US9187497B2 (en) 2015-11-17
WO2010085570A1 (en) 2010-07-29
IL213993A0 (en) 2011-08-31
US20110158989A1 (en) 2011-06-30
AU2010206744A1 (en) 2011-08-04
CL2011001754A1 (es) 2012-01-20
US20100190763A1 (en) 2010-07-29
JP2012515786A (ja) 2012-07-12
EA020301B1 (ru) 2014-10-30
CN102341394A (zh) 2012-02-01
US7928105B2 (en) 2011-04-19
NZ594322A (en) 2013-01-25
PE20120418A1 (es) 2012-05-04
KR20110107396A (ko) 2011-09-30
ECSP11011284A (es) 2011-10-31
US20120122835A1 (en) 2012-05-17
MA33053B1 (fr) 2012-02-01
EA201170963A1 (ru) 2012-03-30
CN102341394B (zh) 2015-04-15
US8450323B2 (en) 2013-05-28
US20130274239A1 (en) 2013-10-17
TN2011000339A1 (en) 2013-03-27
AU2010206744B2 (en) 2015-08-20
DOP2011000237A (es) 2011-09-15
JP5567599B2 (ja) 2014-08-06
EP2389379A1 (en) 2011-11-30
CA2750106A1 (en) 2010-07-29
MY152386A (en) 2014-09-15
KR101779137B1 (ko) 2017-09-18
MX2011007741A (es) 2011-09-06
IL213993A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
BRPI1007358A2 (pt) inibidores de poli (adp-ribose) polimerase (parp)
LTC2767537I2 (lt) Poli(ADP-ribozės)polimerazės (PARP) dihidropiridoftalazinono inhibitoriai
LTPA2018009I1 (lt) Amidu pakeisti indazolai, kaip poli(ADP-ribozės)polimerazės (PARP) inhibitoriai
BRPI0722070A2 (pt) Inibidores de poli(adp-ribose)polimerase
BRPI0913643A2 (pt) inibidores de ciclopropil polimerase
EP2467382A4 (en) AMINO-TETRA HYDRO-pyridopyrimidine PDE10 INHIBITORS
EP2435048A4 (en) RADIOACTIVELY MARKED PDE10 HEMMER
DK2373644T3 (da) Pyridazinonderivater
BRPI0822141A2 (pt) Microfibra
DK2370230T3 (da) Bearbejdningscenter
BR112013009461A2 (pt) inibidores de polimerase vitais
BR112012003059A2 (pt) inibidores de jnk
EP2442839A4 (en) MIXTURES OF BLOCK COPOLYMERS
ES1070817Y (es) Lavabo
IT1394338B1 (it) Dispositivo di bloccaggio di pezzi
IT1395832B1 (it) Dispositivo di chiusura
ES1069853Y (es) Fregadero
DK2373647T3 (da) Pyridazinonderivater
EP2406550A4 (en) VENTILATION EQUIPMENT
HK1163687A (en) Poly (adp-ribose) polymerase (parp) inhibitors
ITVA20070044U1 (it) Abbracciatovagliolo - abbraccia tovagliolo
DK2246118T3 (da) Strålerør
IT1404083B1 (it) Dispositivo di chiusura
ZA200903996B (en) Inhibitors of poly (adp-ribose)polymerase
ES1065735Y (es) Pastilla de jabon con nucleo activo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]